IMCR Logo

Immunocore Holdings plc (IMCR) Stock Forecast & Price Prediction

Live IMCR Stock Price & Analysis

Home โ€บ Stocks โ€บ United Kingdom | NASDAQ | Healthcare | Biotechnology

$29.44

-0.61 (-2.03%)

12 Month Price Forecast For IMCR

$29.44
Current Price
$1.47B
Market Cap
15 Ratings
Buy 12
Hold 2
Sell 1
Wall St Analyst Ratings

Distance to IMCR Price Forecasts

+236.1%
To High Target of $98.94
+116.7%
To Median Target of $63.79
-22.0%
To Low Target of $22.96

IMCR Price Momentum

-3.8%
1 Week Change
-3.2%
1 Month Change
-60.5%
1 Year Change
-0.2%
Year-to-Date Change
-60.9%
From 52W High of $75.30
+6.3%
From 52W Low of $27.69

๐Ÿค” Considering Immunocore (IMCR)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 12, 2025 12:01 AM UTC

IMCR Analyst Ratings & Price Targets

Based on our analysis of 19 Wall Street analysts, IMCR has a bullish consensus with a median price target of $63.79 (ranging from $22.96 to $98.94). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $29.44, the median forecast implies a 116.7% upside. This outlook is supported by 12 Buy, 2 Hold, and 1 Sell ratings.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

IMCR Analyst Consensus

12
Buy
2
Hold
1
Sell

IMCR Price Target Range

Low
$22.96
Average
$63.79
High
$98.94
Current: $29.44

Latest IMCR Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for IMCR.

Date Firm Analyst Rating Change Price Target
Jan 27, 2025 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $100.00
Jan 10, 2025 Needham Buy Reiterates $0.00
Dec 13, 2024 Morgan Stanley Andrew Galler Equal-Weight Downgrade $35.00
Nov 11, 2024 Mizuho Graig Suvannavejh Neutral Downgrade $38.00
Nov 7, 2024 Needham Gil Blum Buy Maintains $71.00
Oct 24, 2024 UBS David Dai Sell Initiates $24.00
Oct 24, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $100.00
Oct 11, 2024 Morgan Stanley Andrew Galler Overweight Maintains $74.00
Oct 7, 2024 Guggenheim Michael Schmidt Neutral Downgrade $0.00
Sep 17, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $100.00
Sep 17, 2024 Needham Gil Blum Buy Maintains $78.00
Sep 9, 2024 Cantor Fitzgerald Eric Schmidt Overweight Reiterates $0.00
Aug 28, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $100.00
Aug 9, 2024 Oppenheimer Jeff Jones Outperform Reiterates $89.00
Aug 9, 2024 Needham Gil Blum Buy Reiterates $81.00
Aug 9, 2024 Barclays Peter Lawson Overweight Maintains $66.00
Jul 10, 2024 JP Morgan Jessica Fye Overweight Maintains $66.00
Jun 5, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $100.00
Jun 3, 2024 Needham Gil Blum Buy Reiterates $81.00
May 30, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $100.00

Stocks Similar to Immunocore Holdings plc

The following stocks are similar to Immunocore based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Immunocore Holdings plc (IMCR) Financial Data

Immunocore Holdings plc has a market capitalization of $1.47B with a P/E ratio of -25.0x. The company generates $296.31M in trailing twelve-month revenue with a -15.9% profit margin.

Revenue growth is +23.7% quarter-over-quarter, while maintaining an operating margin of -10.6% and return on equity of -12.8%.

Valuation Metrics

Market Cap $1.47B
Enterprise Value $1.08B
P/E Ratio -25.0x
PEG Ratio -17.2x
Price/Sales 5.0x

Growth & Margins

Revenue Growth (YoY) +23.7%
Gross Margin +99.4%
Operating Margin -10.6%
Net Margin -15.9%
EPS Growth +864.2%

Financial Health

Cash/Price Ratio +61.2%
Current Ratio 3.8x
Debt/Equity 127.3x
ROE -12.8%
ROA -5.2%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) Company Overview

About Immunocore Holdings plc

What They Do

Develops immunotherapies for cancer and autoimmune diseases.

Business Model

The company operates as a commercial-stage biotechnology firm, generating revenue primarily through the sale of its immunotherapy product KIMMTRAK, which targets specific cancer types. Additionally, Immunocore is advancing a robust pipeline of drug candidates in various stages of clinical trials, aiming to address multiple oncology and autoimmune disease indications, which could contribute to future revenue streams upon successful commercialization.

Additional Information

Founded in 1999 and headquartered in Abingdon, UK, Immunocore is focused on innovative treatments, including programs for advanced cutaneous melanoma and other cancers. The company is actively pursuing multiple clinical trials to expand its product offerings and enhance its market position in the biopharmaceutical sector.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

497

CEO

Dr. Bahija Jallal Ph.D.

Country

United Kingdom

IPO Year

2021

Immunocore Holdings plc (IMCR) Latest News & Analysis

IMCR stock latest news image
Quick Summary

Wall Street analysts project a potential upside of 113.1% for Immunocore (IMCR), supported by positive earnings estimate revisions.

Why It Matters

A 113.1% upside in price targets for Immunocore suggests strong growth potential, while positive earnings revisions may further boost investor confidence and stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
IMCR stock latest news image
Quick Summary

KIMMTRAK (tebentafusp) aims to expand its reach to more mUM patients globally by 2025 through new launches and enhanced community penetration.

Why It Matters

Expansion of KIMMTRAK indicates potential revenue growth for the company, enhancing market presence and possibly impacting stock performance positively.

Source: GlobeNewsWire
Market Sentiment: Neutral
IMCR stock latest news image
Quick Summary

Immunocore will present at the 43rd Annual J.P. Morgan Healthcare Conference, which may highlight its developments and future plans to investors.

Why It Matters

Immunocore's presentation at a major healthcare conference could signal advancements in its pipeline, influencing stock performance and investor sentiment in biotech.

Source: GlobeNewsWire
Market Sentiment: Neutral
IMCR stock latest news image
Quick Summary

AORT, VERX, NN, IMCR, and EVER have been designated as Zacks Rank #1 (Strong Buy) as of January 7, 2024.

Why It Matters

Zacks Rank #1 indicates strong growth potential for AORT, VERX, NN, IMCR, and EVER, suggesting favorable investment opportunities and potential price appreciation.

Source: Zacks Investment Research
Market Sentiment: Positive
IMCR stock latest news image
Quick Summary

Immunocore has appointed Travis Coy as EVP, Chief Financial Officer, and Head of Corporate Development, previously serving as a Non-Executive Director.

Why It Matters

Travis Coy's appointment as CFO and Head of Corporate Development may signal strategic shifts and financial stability, impacting investor confidence and potential stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
IMCR stock latest news image
Quick Summary

Biotech stocks ALLO, DAWN, and IMCR faced declines in 2024 but are considered to have upside potential for 2025.

Why It Matters

The mention of biotech stocks ALLO, DAWN, and IMCR suggests potential recovery opportunities, indicating possible value buys for investors looking for growth in 2025.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About IMCR Stock

What is Immunocore Holdings plc's (IMCR) stock forecast for 2025?

Based on our analysis of 19 Wall Street analysts, Immunocore Holdings plc (IMCR) has a median price target of $63.79. The highest price target is $98.94 and the lowest is $22.96.

Is IMCR stock a good investment in 2025?

According to current analyst ratings, IMCR has 12 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $29.44. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for IMCR stock?

Wall Street analysts predict IMCR stock could reach $63.79 in the next 12 months. This represents a 116.7% increase from the current price of $29.44. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Immunocore Holdings plc's business model?

The company operates as a commercial-stage biotechnology firm, generating revenue primarily through the sale of its immunotherapy product KIMMTRAK, which targets specific cancer types. Additionally, Immunocore is advancing a robust pipeline of drug candidates in various stages of clinical trials, aiming to address multiple oncology and autoimmune disease indications, which could contribute to future revenue streams upon successful commercialization.

What is the highest forecasted price for IMCR Immunocore Holdings plc?

The highest price target for IMCR is $98.94 from at , which represents a 236.1% increase from the current price of $29.44.

What is the lowest forecasted price for IMCR Immunocore Holdings plc?

The lowest price target for IMCR is $22.96 from at , which represents a -22.0% decrease from the current price of $29.44.

What is the overall IMCR consensus from analysts for Immunocore Holdings plc?

The overall analyst consensus for IMCR is bullish. Out of 19 Wall Street analysts, 12 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $63.79.

How accurate are IMCR stock price projections?

Stock price projections, including those for Immunocore Holdings plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.